Search Results

Secondary Analysis of TUXEDO Compares PCI in Patients With Insulin-Treated and Non–Insulin-Treated Diabetes Mellitus

April 25, 2016—Sripal Bangalore, MD, et al published findings from a study conducted to assess the outcomes of patients with insulin-treated diabetes mellitus (ITDM) versus non-ITDM patients who underwent percutaneous coronary intervention (PCI) and to assess the efficacy and safety of an everolimus-eluting stent (EES) versus a paclitaxel-eluting stent (PES) based on insulin use status.

AHA Publishes Scientific Statement on Cardiac Catheterization Lab Practices

June 30, 2021—The American Heart Association (AHA) announced the publication of an AHA scientific statement, “Evidence-Based Practices in the Cardiac Catheterization Laboratory.” The document by Sripal Bangalore, MD, et al is available online ahead of print in Circulation.

Cobalt Chromium EES Compared to CABG in Patients With Diabetes Mellitus

June 17, 2014—A new generation of drug-eluting stents may bridge the gap in outcomes currently seen with percutaneous coronary intervention (PCI) versus coronary artery bypass graft surgery (CABG) to treat patients with diabetes mellitus, according to a study by Sripal Bangalore, MD, et al.

PCI With EES Compares Favorably to CABG in Patients With Diabetes and Multivessel Disease

July 9, 2015—Findings from a comparison of percutaneous coronary intervention (PCI) using everolimus-eluting stents (EES) versus coronary artery bypass graft surgery (CABG) for patients with diabetes mellitus and multivessel disease were published by Sripal Bangalore, MD, et al and are available online ahead of print in Circulation: Cardiovascular Interventions.

Newer-Generation Ultra-Thin DES Compared to Older-Generation Thicker-Strut DES

June 29, 2018—Findings from a meta-analysis of randomized trials comparing newer-generation ultra-thin-strut drug-eluting stents (DES) versus older second-generation thicker-strut DESs for percutaneous coronary intervention (PCI) to treat coronary artery disease were published by Sripal Bangalore, MD, et al online ahead of print in Circulation.

Imperative Care Presents Symphony Thrombectomy System Pivotal Trial in Acute PE

September 18, 2025—Imperative Care, Inc. announced efficacy and safety results from the pivotal SYMPHONY-PE trial.

ISCHEMIA Provides Clarity on Invasive Strategies Versus Medical Therapy to Manage Higher-Risk Patients With Stable Ischemic Heart Disease

November 16, 2019—At the American Heart Association (AHA) scientific sessions 2019, held November 16–18 in Philadelphia, Pennsylvania, Judith S. Hochman, MD, presented findings from the ISCHEMIA trial, which sought to determine the best management strategy for higher-risk patients with stable ischemic heart disease and moderate to severe ischemia on stress testing. John A. Spertus, MD, then presented the quality-of-life (QOL) findings from the ISCHEMIA trial.

Imperative Care’s Symphony Thrombectomy System Cleared for PE

September 2, 2025—Imperative Care, Inc. announced it has received FDA 510(k) clearance of its Symphony thrombectomy system to treat pulmonary embolism (PE).

SMT’s TUXEDO-2 Trial of Supraflex Cruz DES Completes Enrollment in India

August 16, 2024—Sahajanand Medical Technologies (SMT) announced the completion of patient enrollment for the TUXEDO-2 clinical trial.

ISCHEMIA Substudy Evaluates Patients With Intermediate Left Main CAD

May 14, 2020—Findings from a substudy of the ISCHEMIA trial showed that patients with intermediate left main disease (LMD) have a greater risk of cardiovascular events compared with patients without intermediate LMD.

Study Evaluates Outcomes of Catheter-Based Therapy for Patients With Cancer and Intermediate- or High-Risk Pulmonary Embolism

January 11, 2024—A study published online in Catheterization and Cardiovascular Interventions by Leiva et al evaluating outcomes of patients with cancer hospitalized with intermediate- or high-risk pulmonary embolism (PE) found a lower risk of in-hospital death or cardiac arrest and a higher risk of major bleeding after treatment with catheter-based therapies (CBT) as compared with no CBT.